PMV Pharmaceuticals, Inc. (PMVP)
| Market Cap | 66.17M -8.6% |
| Revenue (ttm) | n/a |
| Net Income | -88.53M |
| EPS | -1.56 |
| Shares Out | 75.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,821,937 |
| Open | 1.3400 |
| Previous Close | 1.3100 |
| Day's Range | 0.6600 - 1.3400 |
| 52-Week Range | 0.6600 - 1.9100 |
| Beta | 1.51 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+356.62%) |
| Earnings Date | Nov 10, 2026 |
About PMVP
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PMVP stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 356.62% from the latest price.
News
PMV Pharmaceuticals reports 48% confirmed ORR in PYNNACLE Phase 2 trial
PMV Pharmaceuticals (PMVP) reported updated results from the pivotal Phase 2 portion of the PYNNACLE clinical trial of rezatapopt monotherapy in patients with TP53 Y220C-mutated advanced solid tumors....
PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors
PRINCETON, N.J., Nov. 20, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sma...
PMV Pharmaceuticals reports Q3 EPS (52c), consensus (33c)
“We achieved significant milestones during the third quarter across the organization,” said David Mack, President and Chief Executive Officer of PMV Pharma. “The updated monotherapy interim data demon...
PMV Pharmaceuticals Earnings release: Q3 2026
PMV Pharmaceuticals released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
PMV Pharmaceuticals Quarterly report: Q3 2026
PMV Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 10, 2026.
Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
Late-breaking oral presentation to highlight efficacy data across tumor types and in the ovarian cancer primary analysis population Late-breaking oral presentation to highlight efficacy data across tu...
PMV Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Rezatapopt, a targeted therapy for TP53 Y220C-mutated cancers, shows a 46% ORR and 10-month mDOR in PROC, with NDA submission planned for Q1 and commercial launch by year-end. High biomarker testing rates and strong financials support expansion into additional indications.
PMV Pharmaceuticals Slides: Corporate presentation
PMV Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
PMV Pharmaceuticals appoints Philip Herman as chief commercial officer
PMV Pharmaceuticals (PMVP) announced the appointment of Philip Herman as chief commercial officer, or CCO. Herman will lead the company’s commercial strategy and launch preparation for rezatapopt, PMV...
PMV Pharmaceuticals 42M share Spot Secondary priced at $1.21
TD Cowen is acting as sole book running manager for the offering.
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sma...
PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial
PMV Pharmaceuticals (PMVP) announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multicenter, single-arm, registrational Phase 2 trial is a...
PMV Pharmaceuticals announces common stock, warrants offering
PMV Pharmaceuticals (PMVP) announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in…
PMV Pharma Announces Proposed Public Offering of Securities
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sma...
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sma...
PMV Pharmaceuticals reports Q2 EPS (34c), consensus (40c)
“The PYNNACLE clinical trial continues to progress remarkably well, thanks to the dedication and outstanding execution of the clinical investigators, their teams, and ours,” said David Mack, President...
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sma...
PMV Pharmaceuticals Quarterly report: Q2 2026
PMV Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 14, 2026.
PMV Pharmaceuticals Earnings release: Q2 2026
PMV Pharmaceuticals released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
PMV Pharmaceuticals assumed with a Buy at Ladenburg
Ladenburg assumed coverage of PMV Pharmaceuticals (PMVP) with a Buy rating and $3 price target PMV is developing rezatapopt, a precision drug for the treatment of solid tumors, the analyst…
PMV Pharmaceuticals Transcript: AGM 2026
The meeting featured the election of two directors, approval of executive compensation, and auditor ratification. No shareholder questions were raised, and all proposals passed as recommended by the board.
PMV Pharmaceuticals price target lowered to $5 from $6 at Oppenheimer
Oppenheimer lowered the firm’s price target on PMV Pharmaceuticals (PMVP) to $5 from $6 and keeps an Outperform rating on the shares following quarterly results and business update. Rezatapopt continu...
PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)
“The first quarter was one of continued execution as we advance the PYNNACLE study and remain on track to target an NDA submission for rezatapopt for platinum-resistant/refractory ovarian cancer in…
PMV Pharmaceuticals Quarterly report: Q1 2026
PMV Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
PMV Pharmaceuticals Earnings release: Q1 2026
PMV Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.